Decision Support Tool for Detection of Prostate Lesions on MRI

Background:

According to the American Cancer Society, about 1 in 8 men will be diagnosed with prostate cancer during their lifetime. American Urologic Association guidelines state that magnetic resonance imaging (MRI) of the prostate can improve the diagnosis of prostate cancer but should only be utilized at centers of excellence due to poor performance at non-expert centers. Even in centers of excellence where prostate imaging may improve outcomes for patients in aggregate, there is substantial disagreement among radiologists regarding the detection and grading of lesions suspicious for prostate cancer. Furthermore, prostate MRI interpretation can be very time-intensive, taking up to 45 minutes when performing segmentation tasks needed for some software.

Technology Overview:

This technology is a novel diagnostic platform and AI-based system capable of analyzing multiparametric MRI scans to rapidly and autonomously detect lesions that are suspicious for clinically significant prostate cancer. By enabling a high-precision prostate cancer diagnostic solution that can be easily adopted by non-expert centers, the NGH system would significantly improve cancer diagnosis and detection of clinically significant prostate cancers (those with higher chance for metastases) and subsequent management.

Advantages:

•    High precision.
•    Fast results – less than 45 seconds.
•    Expands access to diagnostic services.

Applications:

The primary application for this technology is the detection of prostate cancer.

Intellectual Property Summary:

Patent Pending
US Patent Application #:18/562,027

Stage of Development: TRL 5

Licensing Status:

This technology is available for licensing.